Two decisions, with different evidence
A clinician helps determine whether a medicine is appropriate. A provider comparison helps you understand how access, billing and follow-up work. The second decision cannot replace the first.
A medication class does not identify a product
GLP-1 terminology groups related treatments, but a specific brand, formulation and indication still matter. Tirzepatide acts at both GIP and GLP-1 receptors; semaglutide is a GLP-1 receptor agonist. Product instructions and clinical suitability are not interchangeable.
Approved and compounded are different categories
Compounded drugs are not FDA-approved. Do not assume an identical ingredient name establishes the same finished product, safety assessment or clinical evidence. Ask the prescriber to explain the proposed formulation and pharmacy.
What a useful service should clarify
Before paying, establish who reviews your health information, what happens if treatment is unsuitable, how you reach clinical help and how refills and cancellation work. Ask about state availability directly.
Sources and scope
Read FDA’s guidance on unapproved GLP-1 drugs for product-status context. For clinical product information, use semaglutide labeling and tirzepatide labeling. This guide explains comparison questions; it is not a clinical treatment recommendation.